$YCBDAug 13, 2026, 8:10 PMAI processed
YCBD Q3 revenue +20% to $5.6M; Oasis/Bluebird momentum
AI Summary
CbdMD (YCBD) reported Q3 FY2026 net sales of $5.6M, up 20% YoY, driven by a 61% increase in wholesale sales, expanded Oasis beverage distribution and the first full-quarter contribution from Bluebird Botanicals. The company still posted an operating loss of about $1.13M and a net loss of ~$1.2M as it absorbed one-time M&A/legal costs, inventory reserves and product/regulatory investments, but implemented cost cuts targeting $100–150k/month and highlighted a federal extension and bipartisan legislation that could ease hemp-beverage regulation.
Positives
- Q3 net sales $5.6M, +20% YoY; wholesale revenue up 61%
- Oasis distribution expanded (new TX partner, South Carolina) with distributor depletions +25% in Q3 and July +34%
- Bluebird Botanicals contributed >$0.5M in its first full quarter; federal extension and Beverage Regulatory Parity Act momentum give regulatory runway
Negatives
- Operating loss of ~$1.13M in Q3 and net loss attributable to common shareholders of ~ $1.2M ($0.11/share)
- Gross margin declined to 54.7% from 61.5% due to shift to wholesale, repacking costs and higher inventory reserves
- Cash on hand ~$2.1M and working capital ~$4.7M (limited liquidity)